The Safety Trade-Off: FDA Announces Nationwide Recall of Adequan Canine Injection Over Glass Fiber Contamination

American Regent Animal Health has initiated a nationwide recall of four lots of Adequan joint injections—two for dogs and two for horses—after internal testing revealed the presence of visible glass fibers. The recall, announced on July 31, 2026, and amplified by the FDA in early August, affects Adequan Canine and Adequan i.m., the only FDA-approved disease-modifying osteoarthritis drugs on the veterinary market.

The affected products are 100 mg/mL multi-dose vials for dogs (lots 3369 and 25011) and 500 mg/5 mL single-dose vials for horses (lots 24416 and 25265P). Because Adequan is administered intramuscularly by licensed veterinarians, the recall reaches deep into the daily operations of thousands of companion-animal and equine clinics across the United States.[1][4]

The mechanism of the hazard is strictly localized but potentially severe. Administering an intramuscular injection contaminated with particulate matter like glass fibers poses significant physical risks to the patient. The FDA and the manufacturer warn that such contamination can cause immediate injection-site pain, severe irritation, swelling, inflammation, and the formation of abscesses or deep-tissue infections. Because the glass fibers are a physical contaminant rather than a chemical one, the risk is tied directly to the injection site rather than systemic toxicity.[1][6]

Despite the severity of the potential hazard, the current clinical fallout appears minimal. Distributed to veterinary clinics, online pharmacies, and wholesalers between May 2024 and January 2026, the affected lots have been in circulation for months. However, American Regent has stated that zero adverse events related to the glass contamination have been reported to date. This suggests the issue was caught during routine retention-sample testing at the manufacturing level rather than triggered by a sudden spike in patient injuries at veterinary clinics.[4][5]

Industry analysts note that this is not an isolated incident for the manufacturer's broader network. Just seven days prior to the Adequan announcement, American Regent's parent company pulled a human drug, Papaverine Hydrochloride Injection, for the exact same defect category: glass and paraformaldehyde particulate matter.

Two recalls citing glass contamination from one manufacturing network, spanning both the human and animal-health sides of the business, point toward a broader fill-finish or vial-sourcing failure rather than a single-lot anomaly. This raises practical questions for wholesalers about how quickly they can requalify remaining Adequan inventory.[3]

The recall strips veterinarians of a foundational therapy, forcing a complex clinical pivot. Unlike standard pain medications, Adequan contains polysulfated glycosaminoglycan, which actively slows cartilage breakdown and promotes joint fluid production. With the supply chain now constrained and no direct generic substitute available, clinics and pet owners are forced into a trade-off analysis between waiting for requalified Adequan stock or pivoting to alternative osteoarthritis management strategies.[2][3]

When evaluating Monoclonal Antibodies (such as Librela) as an alternative, the trade-offs are distinct. [For] Highly effective, once-monthly injection that neutralizes nerve growth factor to eliminate pain signals entirely. [Against] It is strictly a pain-masking agent that does nothing to halt the underlying physical degradation of the joint cartilage.

[Evidence] Clinical trials demonstrate profound mobility improvements within weeks, though radiographic imaging shows continued osteoarthritis progression. [Guidance] This fits well when a dog is in severe, active pain and needs immediate quality-of-life improvement, but does not fit when the primary clinical goal is preserving remaining cartilage in early-stage disease.[3]

When evaluating Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like Carprofen or Meloxicam, the clinical calculus shifts toward accessibility. [For] Broadly available, inexpensive, and highly effective at reducing acute joint inflammation. [Against] Daily oral administration is required, and long-term use carries well-documented risks of gastrointestinal ulceration and hepatic or renal toxicity.

[Evidence] Decades of veterinary data confirm NSAIDs rapidly reduce swelling and pain scores, but require mandatory blood panels every six months to monitor organ function. [Guidance] This fits well when a patient needs short-term relief during an acute flare-up or post-operative recovery, but does not fit when treating senior dogs with pre-existing kidney or liver compromise.[3]

When evaluating Oral Joint Supplements (such as Glucosamine and Chondroitin), the focus moves to preventative care. [For] Available over-the-counter without a prescription, completely safe for long-term use, and easily administered at home. [Against] Bioavailability is notoriously poor, meaning very little of the active ingredient actually reaches the synovial fluid of the joint compared to a direct intramuscular injection.

[Evidence] Peer-reviewed veterinary studies show highly variable efficacy, with many dogs showing no statistically significant improvement over a placebo. [Guidance] This fits well when used as a preventative measure in young, active dogs or as a minor adjunct therapy, but does not fit when attempting to replace the clinical efficacy of an injectable disease-modifying drug like Adequan.[3]

Navigating the immediate aftermath of the recall requires coordination between pet owners and their veterinary providers. The FDA advises that consumers, distributors, and veterinary professionals immediately quarantine and return any vials from the four affected lots. For dogs currently undergoing the standard Adequan loading dose—a rigorous regimen of twice-weekly injections for four weeks—veterinarians are generally recommending a temporary pause in treatment while unaffected lots are sourced, rather than abandoning the protocol entirely.[1][5]

Looking ahead, the veterinary orthopedic community is bracing for a temporary but significant supply gap. The FDA's Center for Veterinary Medicine has not yet assigned a formal recall classification, which will eventually signal the agency's official view on the severity of the hazard. In the meantime, wholesalers are scrambling to verify the safety of their remaining Adequan inventory heading into the busy fall season, leaving clinics to carefully manage their alternative therapies and communicate the trade-offs to anxious pet owners.[3][4]